Meet Ipsen in Canada

Welcome, take a look around and learn more about us.

Our mission

To improve patients’ lives

Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care.

Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare diseases.

With a team of over 90 across our headquarters in Mississauga, Ontario and our research & development facility in Montreal, Quebec, our Canadian operation brings together the best of both worlds: the agility of a start-up, backed by the resources and experience of a global biopharmaceutical company. Ipsen Canada is also a member of Innovative Medicines Canada (IMC).

We bring medicines to patients with the strength of nearly 6,000 employees across the globe, including innovators in our key therapeutic areas.

Download our annual report

 

About

Our science

Our SciencePatients are the heart of our science

That’s why we apply the rigor of data to everything we do, whether we’re working in neurology, oncology, or rare diseases—we strive to leave no patient behind. We’ve shaped our research and development pipeline with a goal of launching at least one new drug or meaningful indication every year.

Oncology

Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at helping patients with neuroendocrine tumors, advanced kidney cancer (renal cell carcinoma) and liver cancer (hepatocellular carcinoma).

Neuroscience

People suffering from neurological disorders are in need of treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, and cervical dystonia in adults.

Rare diseases

We continue to evolve and grow our research efforts in the area of rare and ultra-rare diseases. Given the limited understanding of these diseases, we are committed to addressing patient needs, from supporting diagnosis to treatment with specific investment in pituitary pathologies, growth disorders, and ultra-rare bone diseases, including fibrodysplasia ossificans progressiva, commonly known as FOP.

Our Science

Clinical trials

Clinical trials can lead to medical outcomes that help improve lives, and we thank all of our patients who make this critical research possible through their participation in trials. If you would like to learn more about enrolling in a study, visit Health Canada’s Clinical Trials Database.

©2020 Ipsen Biopharmaceuticals, Inc. All rights reserved. June 2020 CR-CA-000013